MX2017004473A - Formulaciones de betalactamasa y usos de las mismas. - Google Patents

Formulaciones de betalactamasa y usos de las mismas.

Info

Publication number
MX2017004473A
MX2017004473A MX2017004473A MX2017004473A MX2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A
Authority
MX
Mexico
Prior art keywords
beta
lactamase
formulations
lactamase formulations
release
Prior art date
Application number
MX2017004473A
Other languages
English (en)
Inventor
Connelly Sheila
Kaleko Michael
BRISTOL Andrew
Original Assignee
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics Inc filed Critical Synthetic Biologics Inc
Publication of MX2017004473A publication Critical patent/MX2017004473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona, en parte, formulaciones que comprenden una betalactamasa. En particular, se proporcionan formulaciones de liberación modificada que comprende una betalactamasa que liberan una cantidad sustancial de la betalactamasa en los intestinos. También se proporcionan usos terapéuticos de las formulaciones de betalactamasa.
MX2017004473A 2014-10-08 2015-10-08 Formulaciones de betalactamasa y usos de las mismas. MX2017004473A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462061507P 2014-10-08 2014-10-08
US201562126556P 2015-02-28 2015-02-28
US201562205443P 2015-08-14 2015-08-14
PCT/US2015/054606 WO2016057744A1 (en) 2014-10-08 2015-10-08 Beta-lactamase formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2017004473A true MX2017004473A (es) 2017-10-12

Family

ID=55653744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004473A MX2017004473A (es) 2014-10-08 2015-10-08 Formulaciones de betalactamasa y usos de las mismas.

Country Status (10)

Country Link
US (3) US10105322B2 (es)
EP (1) EP3204495B1 (es)
JP (1) JP6672277B2 (es)
KR (1) KR102467968B1 (es)
CN (1) CN107148473B (es)
AU (1) AU2015330937B2 (es)
CA (1) CA2962959C (es)
ES (1) ES2806426T3 (es)
MX (1) MX2017004473A (es)
WO (1) WO2016057744A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106574273B (zh) 2014-08-28 2021-07-02 合成生物制品有限公司 β-内酰胺酶的基于大肠杆菌的生产
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11517614B2 (en) 2016-06-28 2022-12-06 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
CN116270991A (zh) * 2016-11-01 2023-06-23 合成生物制品有限公司 用于减弱抗生素抗性的方法和组合物
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
US20200108130A1 (en) * 2017-03-21 2020-04-09 Synthetic Biologics, Inc. Beta-lactamase formulations
CN111247246A (zh) * 2017-10-25 2020-06-05 达·沃尔泰拉公司 β-内酰胺酶变体
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2021533150A (ja) * 2018-08-05 2021-12-02 ダ・ヴォルテッラ 移植片対宿主病の治療のための組成物
US20220218800A1 (en) * 2019-05-06 2022-07-14 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
EP4100876A4 (en) * 2020-03-10 2024-02-28 AI:ON Innovations, Inc. SYSTEM AND METHODS FOR MAMMAL TRANSFER LEARNING
CN112137984B (zh) * 2020-10-30 2023-02-03 四川制药制剂有限公司 头孢克洛胶囊及其制备工艺

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL197650A (es) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
JP2813809B2 (ja) * 1989-06-19 1998-10-22 武田薬品工業株式会社 有核顆粒製剤およびその製造法
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
CN1190434A (zh) 1995-07-07 1998-08-12 诺沃挪第克公司 用不能形成芽孢的芽孢杆菌生产蛋白质的方法
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
AR019935A1 (es) * 1998-07-28 2002-03-27 Takeda Pharmaceutical Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
FI4533U1 (fi) * 2000-03-14 2000-08-10 Finnzymes Oy Entsyymikoostumus maidon käsittelemiseksi
CN100439492C (zh) 2001-05-29 2008-12-03 花王株式会社 宿主微生物
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
EP1883396B1 (en) 2005-05-18 2013-07-03 DA Volterra Colonic delivery of adsorbents
MX2008011441A (es) * 2006-03-06 2008-11-18 Pozen Inc Formas de dosificacion para administrar combinaciones de farmacos.
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CN102946872A (zh) * 2010-05-03 2013-02-27 阿普塔利斯制药有限公司 包含含有胰酶的消化酶混合物的微丸组合物
FI20105572A0 (fi) * 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
WO2013015388A1 (ja) * 2011-07-26 2013-01-31 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｎｄｍ阻害剤
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
US9433632B2 (en) * 2011-11-30 2016-09-06 Takeda Pharmaceutical Company Limited Dry coated tablet
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
CA2942971C (en) * 2014-04-17 2023-03-14 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
WO2016105498A1 (en) * 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
US10709773B2 (en) * 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection

Also Published As

Publication number Publication date
WO2016057744A1 (en) 2016-04-14
US20160101058A1 (en) 2016-04-14
AU2015330937B2 (en) 2021-07-15
EP3204495A1 (en) 2017-08-16
EP3204495B1 (en) 2020-04-22
US20210007994A1 (en) 2021-01-14
US20180360762A1 (en) 2018-12-20
ES2806426T3 (es) 2021-02-17
KR20170065649A (ko) 2017-06-13
KR102467968B1 (ko) 2022-11-16
US10105322B2 (en) 2018-10-23
US10828260B2 (en) 2020-11-10
CN107148473B (zh) 2021-08-06
AU2015330937A1 (en) 2017-05-25
EP3204495A4 (en) 2018-04-18
CA2962959C (en) 2023-04-04
CN107148473A (zh) 2017-09-08
JP2017535521A (ja) 2017-11-30
CA2962959A1 (en) 2016-04-14
JP6672277B2 (ja) 2020-04-01

Similar Documents

Publication Publication Date Title
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
IL249370A0 (en) Fap-enabled medical substances and related uses
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
EP3556368A4 (en) THERAPEUTIC FOR ONYCHOMYCOSIS
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
EP3188721A4 (en) Human therapeutic agents
GB201603104D0 (en) Therapeutic agents
PH12017500602A1 (en) Methods for treating ocular conditions
ZA201906271B (en) Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
GB201418809D0 (en) Therapeutic agents and uses thereof
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
GB201600376D0 (en) Novel therapeutic agents
HK1258464A1 (zh) 新的治療用途
GB201712992D0 (en) New medical uses
GB201704107D0 (en) New medical uses
GB201620948D0 (en) Therapeutic agents
GB201614847D0 (en) Dextranase medicament
GB201616563D0 (en) Therapeutic agents
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния